STANFORD, CA – April 24, 2024 – A protein, long celebrated for its vital role in stimulating red blood cell production, has now been unmasked as a clandestine orchestrator in cancer’s defense against the immune system. In a groundbreaking study published today in Science, researchers have unveiled that erythropoietin (EPO), identified nearly four decades ago, plays a surprisingly critical and detrimental role in dampening the body’s immune response to cancer. This revelation could fundamentally reshape cancer treatment strategies, particularly for aggressive, immune-resistant tumours.
The research demonstrates that blocking EPO’s activity can transform previously "cold" – or immune-resistant – liver tumours in mice into "hot" tumours, teeming with potent cancer-fighting immune cells. When this blockade was combined with existing immunotherapy designed to further activate these immune cells, the results were dramatic: complete regression of existing liver tumours in the majority of treated mice, which subsequently lived for the entire duration of the experiment. In stark contrast, control animals succumbed to the disease within weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," declared Dr. Edgar Engleman, a professor of pathology and medicine at Stanford University, and the senior author of the research. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials."
The study, led by basic life research scientist Dr. David Kung-Chun Chiu, represents a paradigm shift in how the scientific community perceives EPO, moving it beyond its well-established hematopoietic function into the complex realm of immuno-oncology.
Chronology of a Revelation: From Red Blood Cells to Immune Suppression
The journey to understanding EPO’s multifaceted nature has been a long and winding one, spanning nearly 40 years of scientific inquiry. Initially identified in the 1980s, erythropoietin quickly gained prominence for its essential role in erythropoiesis – the production of red blood cells. Its clinical application in treating anemia, particularly in patients with kidney disease or those undergoing chemotherapy, became widespread. However, the story took a darker turn in the early 2000s when a disconcerting pattern began to emerge in cancer patients.
The Early Warning Signs: A Troubling Connection
"Research from more than a decade ago has shown that giving EPO to cancer patients with anemia to stimulate red blood cell formation accelerates the growth of the tumor," Dr. Engleman recounted, highlighting a long-standing clinical enigma. This alarming observation led to a significant regulatory intervention in 2007, when the U.S. Food and Drug Administration (FDA) mandated a black box warning label on EPO-stimulating drugs, cautioning against their use in individuals with certain cancers.
Further retrospective analyses strengthened this unsettling correlation. Researchers observed a clear and consistent link between elevated levels of naturally occurring EPO and its receptor (EPOR) within tumours, and a poorer prognosis for cancer patients. "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman explained. Yet, despite these compelling clinical correlations, the precise mechanism linking EPO to accelerated tumour growth remained elusive. The scientific community largely attributed EPO’s adverse effect to its potential to directly stimulate cancer cell proliferation, or to enhance the tumour’s blood supply. The possibility of an immune system connection was simply not on the radar.
The Missing Link: EPO and Cancer Immunity
"But the connection between EPO and cancer immunity was never made until now," Dr. Engleman emphasized. "In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." This historical perception created a significant blind spot, making the recent discovery all the more unexpected and impactful.
The breakthrough stemmed from Dr. Chiu’s meticulous work in developing sophisticated mouse models of liver cancer. Utilizing advanced genome editing techniques, Dr. Chiu engineered various mouse models that accurately recapitulated specific mutations, histologies, and responses to approved therapies observed in distinct subtypes of human liver cancers. Tumour formation was initiated either by injecting a carefully selected combination of DNA encoding liver cancer-associated proteins into the animals’ tail veins or by directly implanting liver cancer cells into their livers. This comprehensive modelling provided a robust platform to investigate the complex interplay between tumour biology and therapeutic interventions.
Investigating Immunotherapy Resistance
The primary focus of Dr. Chiu’s team was to understand why many cancers, particularly liver cancer, remain resistant to cutting-edge immunotherapies. They were particularly interested in the effects of therapies targeting programmed cell death protein 1 (PD-1), a molecule expressed on immune cells, especially T cells. Anti-PD-1 therapies, such as the commercially available Keytruda, work by blocking the ability of cancer cells to "turn off" T cells, thereby unleashing the T cells’ inherent ability to attack and destroy malignant cells. While these therapies have revolutionized the treatment of certain cancers like melanoma, Hodgkin’s lymphoma, and some lung cancers, a vast majority of tumours—including most liver, pancreas, colon, breast, and prostate cancers—remain stubbornly resistant.
The researchers observed, consistent with human liver cancers, that some combinations of genetic mutations led to the development of "cold" tumours. These tumours were largely ignored by the immune system, characterized by a scarce infiltration of T cells and, consequently, showed no shrinkage when treated with anti-PD-1 therapy. In stark contrast, other genetic alterations resulted in "hot" or "inflamed" tumours. These tumours were rich in T cells and highly sensitive to anti-PD-1 treatment, which effectively triggered the T cells to mount a robust anti-cancer assault.
The Unexpected Culprit: EPO’s Elevation in Cold Tumours
The critical turning point came with an unexpected observation: the cold, immune-resistant tumours displayed significantly elevated levels of EPO compared to their hot counterparts. This increase was traced back to the oxygen-poor microenvironment, a condition known as hypoxia, which is notoriously prevalent within rapidly growing, poorly vascularized cold tumours. Hypoxia is a known inducer of various proteins in cancer cells, which in turn can ramp up the production of EPO in an attempt to stimulate red blood cell formation and thus alleviate the low oxygen levels.
"Hypoxia in tumors has been studied for decades," Dr. Engleman noted, underscoring the long-standing knowledge gap. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This insight sparked a new line of inquiry, compelling the researchers to re-evaluate EPO’s role beyond its established hematopoietic function.
Supporting Data: Unpacking the Mechanism
Armed with this surprising correlation, the team delved deeper. They first leveraged existing public databases, confirming that elevated EPO levels are indeed associated with poorer survival rates across a broad spectrum of human cancers, including those of the liver, kidney, breast, colon, and skin. This broad applicability underscored the potential generalizability of their findings.
The subsequent experiments in mouse models were meticulously designed to directly test the causal link between EPO and immune suppression. The results were compelling and unequivocally demonstrated EPO’s profound impact on tumour immunity:
- Manipulating EPO Production: Mutations that previously led to the development of cold tumours instead caused hot tumours when those tumour cells were genetically modified to be incapable of producing EPO. This direct manipulation clearly showed that EPO production by the tumour itself was a key determinant of its immune status.
- Engineering Immunosuppression: Conversely, hot tumours that had previously been successfully eradicated by the immune system, particularly with anti-PD-1 treatment, thrived and grew aggressively when they were engineered to produce elevated levels of EPO. This experiment provided powerful evidence that increased EPO directly confers immune evasion capabilities upon tumours.
The EPO-Macrophage Axis: A Molecular Handshake of Suppression
Further exhaustive research painstakingly elucidated the precise molecular mechanism by which EPO exerts its immunosuppressive effects. In cold tumours, the cancer cells actively synthesize and secrete EPO into the tumour microenvironment. This secreted EPO then binds to specific receptors located on the surface of immune cells known as macrophages.
Macrophages are highly versatile immune cells that can adopt different phenotypes, either promoting inflammation and anti-tumour responses (M1-like macrophages) or fostering immune suppression and tissue repair (M2-like macrophages). The researchers discovered that when EPO binds to its receptors on macrophages, it triggers a signaling cascade that effectively reprograms these macrophages. They switch to an immunosuppressive, M2-like role, actively "shooing away" cancer-killing T cells from the tumour site and dampening the activity of any T cells that manage to infiltrate. This EPO-mediated crosstalk between tumour cells and macrophages creates a protective immunological shield around the tumour, rendering it invisible and invulnerable to the host’s immune system.
The Power of Combination Therapy
The clinical significance of this EPO-moderated crosstalk became strikingly clear when the researchers investigated the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. These experiments represented the ultimate test of their hypothesis, aiming to convert resistant tumours into treatable ones.
The results were unequivocal:
- In control groups, mice with cold liver tumours treated with either a placebo or anti-PD-1 therapy alone survived no more than eight weeks after tumour induction. This reiterated the inherent resistance of these tumours to conventional immunotherapy.
- However, in mice whose macrophages were genetically engineered to be unable to produce the EPO receptor – effectively blocking EPO signaling – 40% lived for 18 weeks after tumour induction, at which point the experiment was terminated. This demonstrated that simply disrupting EPO signaling could significantly prolong survival and enhance immune recognition.
- The most profound outcome was observed when anti-PD-1 treatment was administered to mice lacking the EPO receptor: all animals lived for the entire duration of the experiment, achieving complete and sustained tumour regression.
"It’s simple," Dr. Engleman summarized, underscoring the elegance and power of the discovery. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This finding suggests a potent strategy for overcoming one of the most significant challenges in modern immuno-oncology: primary resistance to checkpoint inhibitors.
Official Responses and Expert Perspectives
The scientific community is poised to receive this finding with considerable excitement and anticipation. Dr. Engleman’s personal enthusiasm reflects the profound implications of the work. His statement, "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials," encapsulates the urgency and promise of translating this basic science into tangible patient benefits.
The historical context of EPO’s "black box warning" and the long-standing mystery surrounding its pro-tumour effects lend significant weight to this new understanding. For years, clinicians and researchers knew EPO was bad for cancer patients, but they didn’t fully understand why. This study provides a mechanistic explanation, transforming a clinical observation into a targetable pathway. The fact that the research took "a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer" highlights the ingrained perception of EPO as solely a red blood cell growth factor. This intellectual hurdle makes the ultimate breakthrough even more compelling.
The simplicity of the proposed therapeutic intervention – targeting a single signaling pathway to fundamentally alter the immune landscape of a tumour – is a testament to the power of basic research. The clarity of the results in the mouse models provides a strong foundation for future clinical development, generating optimism among oncologists and immunologists alike.
Implications for Future Cancer Therapies
The implications of this discovery are vast and potentially transformative for a wide array of human cancers. While the current work was conducted in mouse models of liver cancer, the strong indications of EPO’s similar role in many types of human cancers, supported by existing patient data correlating elevated EPO with poorer prognoses in liver, kidney, breast, colon, and skin cancers, suggest broad applicability.
Broadening the Reach of Immunotherapy
The most immediate and impactful implication is the potential to render a large proportion of currently "cold" and immunotherapy-resistant tumours susceptible to existing checkpoint inhibitors like anti-PD-1 therapies. This could expand the utility of these life-saving drugs to patients suffering from cancers that currently have limited effective treatment options. Liver cancer, specifically hepatocellular carcinoma, is a leading cause of cancer-related death worldwide, and its notorious resistance to many systemic therapies makes this discovery particularly pertinent.
Developing Novel Therapeutic Strategies
Dr. Engleman and his colleagues are already actively designing treatments targeting EPO signaling in human cancers. Several potential strategies are being considered:
- Non-specific EPO Targeting: One approach involves broadly reducing EPO levels or activity. This strategy, while potentially effective, carries a significant trade-off: it could induce anemia, given EPO’s primary role in red blood cell production. However, Dr. Engleman speculates that for patients facing aggressive, life-threatening cancers, the potential for an effective cancer therapy might make anemia an acceptable, manageable side effect. Clinical trials would need to carefully balance efficacy against quality of life.
- Selective EPO Receptor Blockade on Macrophages: A more refined and potentially less toxic approach would be to selectively block the EPO receptors specifically on the surfaces of macrophages within the tumour microenvironment. This targeted strategy aims to disarm the immunosuppressive macrophages without interfering with EPO’s systemic red blood cell production. Such an approach would likely involve novel small molecules or antibodies designed to specifically bind to macrophage EPO receptors.
Beyond Current Boundaries
This discovery also opens new avenues for understanding the complex interplay between hypoxia, metabolism, and immune evasion in the tumour microenvironment. It underscores how cancer cells cleverly co-opt normal physiological pathways for their own survival and proliferation. Future research may explore other hypoxia-induced factors and their potential roles in immune suppression.
The collaboration across institutions, including researchers from the New York Blood Center and the pharmaceutical company ImmunEdge Inc., highlights the multidisciplinary effort required for such complex discoveries. The study was generously funded by the National Institutes of Health, a testament to the scientific rigor and potential impact recognized by major funding bodies.
As with any major scientific breakthrough, there are challenges ahead. Translating these findings from mouse models to human clinical trials requires meticulous planning, careful dose-finding studies, and rigorous safety assessments. Not every tumour will respond in the exact same way, and patient heterogeneity will need to be carefully considered. However, Dr. Engleman remains profoundly optimistic. "I continue to be amazed by this finding," he stated. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies."
This research, spearheaded by Dr. Chiu and Dr. Engleman, who are also cofounders and stakeholders in ImmunEdge Inc. and inventors on a related patent application (PCT/US2023/063997, "EPO receptor agonists and antagonists"), signifies a pivotal moment in immuno-oncology. By demystifying EPO’s role as an immune suppressor, scientists have illuminated a new path toward turning the tide against some of the most challenging and resistant cancers, offering renewed hope for patients worldwide.
About the Author
